After listening to the enterprise AI specialist's latest earnings call, I have some concerns over where the company is headed ...

Investors should always rely on their own analysis, not just management talk and projections, when deciding whether to buy a ...

C3.ai's growth is fairly modest given its size and the strength of the demand environment. Read why I remain neutral on AI ...

Cannabinoid-focused biopharmaceutical company C3 Pharmaceuticals announces a planned listing on the Canadian Securities ...

Shares of C3.ai Inc. AI sank 0.26% to $23.27 Wednesday, on what proved to be an all-around grim trading session for the stock ...

The new iteration of C3 Pharmaceuticals, Inc. announced that it executed a tailored Share Subscription Agreement (SSA) with ...

This was the stock's fourth consecutive day of gains.

Enterprises and institutions are rushing to develop an AI strategy, which will be a tailwind for these two AI stocks.

C3.ai, Inc. (AI) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some ...

Executives are fighting back against a federal court decision that banned them from the securities industry and ordered them ...

We recently published a list of 10 AI News and Analyst Ratings You Should Not Miss. Since C3.ai Inc (NYSE:AI) ranks 10th on ...

A coding challenge designed for elementary-age students. The goal of C3 Jr. Is to encourage and inspire students to learn ...